Archive

FDA HCT/P Draft Guidance Documents Meetings

FDA Certified MiMedx Allografts for Marketing in the United States and Export

Letter to Commissioner Califf from 4 U.S. Senator’s on Draft Guidance

MiMedx Amniotic Allografts Are Terminally Sterilized to Enhance Safety Related to Microbiological and Viral Transmission

MiMedx Announces U.S. Pharmacopeia Monograph For dHACM Allografts Has Published

Hurricane Irma Relief Efforts

Company Relief Efforts for Employees Impacted by Hurricane Harvey

Resources

Contact Us

1775 West Oak Commons Ct.
Marietta, GA 30062
(888) 543-1917 (toll-free)
(770) 651-9100 (local)
Facebook-f Twitter Linkedin-in Vimeo-v
Manage Cookie Preferences

MIMEDX® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues. This website is not meant as a substitute for professional medical advice.

This link leads to the machine readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine-readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.

© 2023 MIMEDX Group, Inc. All rights reserved.

Version 016